[1]
Shafer RW, Vuitton DA. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 1999 Mar:53(2):73-86
[PubMed PMID: 10337461]
[2]
Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. The New England journal of medicine. 1996 Mar 14:334(11):701-6
[PubMed PMID: 8594430]
[3]
Cunningham WE,Tisnado DM,Lui HH,Nakazono TT,Carlisle DM, The effect of hospital experience on mortality among patients hospitalized with acquired immunodeficiency syndrome in California. The American journal of medicine. 1999 Aug;
[PubMed PMID: 10460044]
[4]
Rackal JM, Tynan AM, Handford CD, Rzeznikiewiz D, Agha A, Glazier R. Provider training and experience for people living with HIV/AIDS. The Cochrane database of systematic reviews. 2011 Jun 15:(6):CD003938. doi: 10.1002/14651858.CD003938.pub2. Epub 2011 Jun 15
[PubMed PMID: 21678344]
Level 1 (high-level) evidence
[5]
Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, Mills EJ, Meintjes G, Vitoria M, Doherty M, Shubber Z. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS (London, England). 2018 Jan 2:32(1):17-23. doi: 10.1097/QAD.0000000000001671. Epub
[PubMed PMID: 29112073]
[6]
Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12:316(2):191-210. doi: 10.1001/jama.2016.8900. Epub
[PubMed PMID: 27404187]
[7]
INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. The New England journal of medicine. 2015 Aug 27:373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20
[PubMed PMID: 26192873]
[8]
Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25:308(4):387-402. doi: 10.1001/jama.2012.7961. Epub
[PubMed PMID: 22820792]
[9]
Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. The New England journal of medicine. 2009 Dec 3:361(23):2230-40. doi: 10.1056/NEJMoa0906768. Epub 2009 Dec 1
[PubMed PMID: 19952143]
[10]
Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Journal of acquired immune deficiency syndromes (1999). 2010 Sep:55(1):49-57. doi: 10.1097/QAI.0b013e3181dd911e. Epub
[PubMed PMID: 20431394]
Level 1 (high-level) evidence
[11]
Hoffman RM, Black V, Technau K, van der Merwe KJ, Currier J, Coovadia A, Chersich M. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. Journal of acquired immune deficiency syndromes (1999). 2010 May 1:54(1):35-41. doi: 10.1097/QAI.0b013e3181cf9979. Epub
[PubMed PMID: 20216425]
[12]
Read PJ, Mandalia S, Khan P, Harrisson U, Naftalin C, Gilleece Y, Anderson J, Hawkins DA, Taylor GP, de Ruiter A, London HIV Perinatal Research Group. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS (London, England). 2012 Jun 1:26(9):1095-103. doi: 10.1097/QAD.0b013e3283536a6c. Epub
[PubMed PMID: 22441248]
[13]
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J, PARTNER Study Group. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016 Jul 12:316(2):171-81. doi: 10.1001/jama.2016.5148. Epub
[PubMed PMID: 27404185]
[14]
Forbes JC, Alimenti AM, Singer J, Brophy JC, Bitnun A, Samson LM, Money DM, Lee TC, Lapointe ND, Read SE, Canadian Pediatric AIDS Research Group (CPARG). A national review of vertical HIV transmission. AIDS (London, England). 2012 Mar 27:26(6):757-63. doi: 10.1097/QAD.0b013e328350995c. Epub
[PubMed PMID: 22210635]
[15]
European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2005 Feb 1:40(3):458-65
[PubMed PMID: 15668871]
[16]
Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM, iPrEx Study Team. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science translational medicine. 2012 Sep 12:4(151):151ra125
[PubMed PMID: 22972843]
[17]
Menéndez-Arias L, Alvarez M. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral research. 2014 Feb:102():70-86. doi: 10.1016/j.antiviral.2013.12.001. Epub 2013 Dec 15
[PubMed PMID: 24345729]
[18]
Balestre E, Ekouevi DK, Tchounga B, Eholie SP, Messou E, Sawadogo A, Thiébaut R, May MT, Sterne JA, Dabis F, International Epidemiological Database to Evaluate AIDS (IeDEA) West Africa Collaboration. Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort. Journal of the International AIDS Society. 2016:19(1):20044. doi: 10.7448/IAS.19.1.20044doi: 20044. Epub 2016 Feb 8
[PubMed PMID: 26861115]
[19]
Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology (Baltimore, Md.). 2000 Oct:32(4 Pt 1):866-7
[PubMed PMID: 11003636]
[20]
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW, HBV 99-01 Study Group, Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (London, England). 2005 Jan 8-14:365(9454):123-9
[PubMed PMID: 15639293]
Level 1 (high-level) evidence
[21]
Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Annals of internal medicine. 2005 Feb 15:142(4):240-50
[PubMed PMID: 15710957]
Level 1 (high-level) evidence
[22]
Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical therapeutics. 2000 Jun:22(6):685-708
[PubMed PMID: 10929917]
[23]
Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ Jr, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 Jul 24:320(4):379-396. doi: 10.1001/jama.2018.8431. Epub
[PubMed PMID: 30043070]
[24]
. Nucleoside Analogues. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():
[PubMed PMID: 31644243]
[25]
Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Annals of internal medicine. 2014 Oct 7:161(7):461-71. doi: 10.7326/M14-1084. Epub
[PubMed PMID: 25285539]
Level 1 (high-level) evidence
[26]
Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. The Annals of pharmacotherapy. 2010 Jan:44(1):145-56. doi: 10.1345/aph.1M309. Epub 2009 Dec 29
[PubMed PMID: 20040702]
[27]
Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (New York, N.Y.). 2000 Jan 28:287(5453):646-50
[PubMed PMID: 10649997]
[28]
Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrobial agents and chemotherapy. 2005 Nov:49(11):4721-32
[PubMed PMID: 16251317]
[29]
Huesgen E, DeSear KE, Egelund EF, Smith R, Max B, Janelle J. A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios. Pharmacotherapy. 2016 Nov:36(11):1145-1165. doi: 10.1002/phar.1835. Epub 2016 Oct 20
[PubMed PMID: 27636237]
[30]
Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, Jacobson LP. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Nov 15:45(10):1377-85
[PubMed PMID: 17968839]
[31]
Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC, HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Nov 1:59(9):e96-138. doi: 10.1093/cid/ciu617. Epub 2014 Sep 17
[PubMed PMID: 25234519]
Level 1 (high-level) evidence
[32]
Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs. 2005:65(3):413-32
[PubMed PMID: 15669881]
[33]
Chen YF, Stampley JE, Irving BA, Dugas TR. Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence. Toxicological sciences : an official journal of the Society of Toxicology. 2019 Dec 1:172(2):445-456. doi: 10.1093/toxsci/kfz203. Epub
[PubMed PMID: 31545371]
[34]
Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proceedings of the National Academy of Sciences of the United States of America. 2004 Mar 23:101(12):4180-5
[PubMed PMID: 15024131]
[36]
Chang JL, Tsai AC, Musinguzi N, Haberer JE, Boum Y, Muzoora C, Bwana M, Martin JN, Hunt PW, Bangsberg DR, Siedner MJ. Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. Annals of internal medicine. 2018 Aug 7:169(3):146-155. doi: 10.7326/M17-2252. Epub 2018 Jun 26
[PubMed PMID: 29946683]
[37]
Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Annals of internal medicine. 1997 Nov 15:127(10):948
[PubMed PMID: 9382376]
[38]
Soliman EZ, Lundgren JD, Roediger MP, Duprez DA, Temesgen Z, Bickel M, Shlay JC, Somboonwit C, Reiss P, Stein JH, Neaton JD, INSIGHT SMART Study Group. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS (London, England). 2011 Jan 28:25(3):367-77. doi: 10.1097/QAD.0b013e328341dcc0. Epub
[PubMed PMID: 21150558]
[39]
Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV medicine. 2017 Jan:18(1):56-63. doi: 10.1111/hiv.12468. Epub 2016 Nov 10
[PubMed PMID: 27860104]
[40]
Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, Hsu R, Fusco J, Quercia R, Aboud M, Curtis L. Psychiatric Symptoms in Patients Receiving Dolutegravir. Journal of acquired immune deficiency syndromes (1999). 2017 Apr 1:74(4):423-431. doi: 10.1097/QAI.0000000000001269. Epub
[PubMed PMID: 27984559]
[41]
Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. The New England journal of medicine. 2018 Sep 6:379(10):979-981. doi: 10.1056/NEJMc1807653. Epub 2018 Jul 24
[PubMed PMID: 30037297]
[42]
Gutiérrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS reviews. 2014 Oct-Dec:16(4):199-212
[PubMed PMID: 25350530]
[43]
Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy. 2004 Feb:24(2):198-211
[PubMed PMID: 14998221]
[44]
Miao M, De Clercq E, Li G. Clinical significance of chemokine receptor antagonists. Expert opinion on drug metabolism & toxicology. 2020 Jan:16(1):11-30. doi: 10.1080/17425255.2020.1711884. Epub 2020 Jan 17
[PubMed PMID: 31903790]
Level 3 (low-level) evidence
[45]
De Luca A, Pezzotti P, Boucher C, Döring M, Incardona F, Kaiser R, Lengauer T, Pfeifer N, Schülter E, Vandamme AM, Zazzi M, Geretti AM, EucoHIV Study Group. Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey. PloS one. 2019:14(11):e0225381. doi: 10.1371/journal.pone.0225381. Epub 2019 Nov 21
[PubMed PMID: 31751385]
Level 3 (low-level) evidence
[46]
de Ruiter A, Taylor GP, Clayden P, Dhar J, Gandhi K, Gilleece Y, Harding K, Hay P, Kennedy J, Low-Beer N, Lyall H, Palfreeman A, O'Shea S, Tookey P, Tosswill J, Welch S, Wilkins E, British HIV Association. British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV medicine. 2014 Sep:15 Suppl 4():1-77. doi: 10.1111/hiv.12185. Epub
[PubMed PMID: 25604045]
[47]
Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS (London, England). 2004 May 21:18(8):1169-77
[PubMed PMID: 15166532]
[48]
Zdanowicz MM. The pharmacology of HIV drug resistance. American journal of pharmaceutical education. 2006 Oct 15:70(5):100
[PubMed PMID: 17149429]
[49]
Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Aug 1:47(3):421-4. doi: 10.1086/589867. Epub
[PubMed PMID: 18558886]
[50]
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of internal medicine. 2000 Jul 4:133(1):21-30
[PubMed PMID: 10877736]
[51]
Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Jan:58(1):e1-34. doi: 10.1093/cid/cit665. Epub 2013 Nov 13
[PubMed PMID: 24235263]
[52]
Freedberg KA, Malabanan A, Samet JH, Libman H. Initial assessment of patients infected with human immunodeficiency virus: the yield and cost of laboratory testing. Journal of acquired immune deficiency syndromes. 1994 Nov:7(11):1134-40
[PubMed PMID: 7932080]
[53]
Günthard HF, Calvez V, Paredes R, Pillay D, Shafer RW, Wensing AM, Jacobsen DM, Richman DD. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 Jan 7:68(2):177-187. doi: 10.1093/cid/ciy463. Epub
[PubMed PMID: 30052811]